APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Targeted Drugs for Neurodegenerative Diseases

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Targeted Drugs for Neurodegenerative Diseases Market Outlook and Growth Opportunities 2026

Report ID 174039780427 December 2025200 pages

Choose your research edition.

Industry ResearchTargeted Drugs for Neurodegenerative Diseases Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeted Drugs for Neurodegenerative Diseases Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Targeted Drugs for Neurodegenerative Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeted Drugs for Neurodegenerative Diseases Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeted Drugs for Neurodegenerative Diseases Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Targeted Drugs for Neurodegenerative Diseases market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Targeted Drugs for Neurodegenerative Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Targeted Drugs for Neurodegenerative Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeted Drugs for Neurodegenerative Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Targeted Drugs for Neurodegenerative Diseases market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Targeted Drugs for Neurodegenerative Diseases market include Eisai Inc., Teva, NOVARTIS, Green Valley, Roche, Lundbeck, Eli Lilly, Biogen and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Targeted Drugs for Neurodegenerative Diseases market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Targeted Drugs for Neurodegenerative Diseases and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Targeted Drugs for Neurodegenerative Diseases revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Targeted Drugs for Neurodegenerative Diseases market.

Targeted Drugs for Neurodegenerative Diseases Segment by Company

Eisai Inc.

Teva

NOVARTIS

Green Valley

Roche

Lundbeck

Eli Lilly

Biogen

UCB

Supernus Pharmaceuticals

Sumitomo Pharma

Sanofi

Neurocrine

Kyowa Kirin

Janssen

Bristol-Myers Squibb

Acadia Pharmaceuticals Inc.

Targeted Drugs for Neurodegenerative Diseases Segment by Type

Oral

Injection

Targeted Drugs for Neurodegenerative Diseases Segment by Application

Parkinson's Disease (PD)

Huntington's Disease (HD)

Multiple Sclerosis (MS)

Tardive Dyskinesia (TD)

Alzheimer's Disease (AD)

Targeted Drugs for Neurodegenerative Diseases Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Targeted Drugs for Neurodegenerative Diseases status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Targeted Drugs for Neurodegenerative Diseases key companies, revenue, market share, and recent developments.

3. To split the Targeted Drugs for Neurodegenerative Diseases breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Targeted Drugs for Neurodegenerative Diseases market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Targeted Drugs for Neurodegenerative Diseases significant trends, drivers, influence factors in global and regions.

6. To analyze Targeted Drugs for Neurodegenerative Diseases competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Neurodegenerative Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Neurodegenerative Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Neurodegenerative Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeted Drugs for Neurodegenerative Diseases industry.

Chapter 3: Detailed analysis of Targeted Drugs for Neurodegenerative Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Targeted Drugs for Neurodegenerative Diseases in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Targeted Drugs for Neurodegenerative Diseases in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Targeted Drugs for Neurodegenerative Diseases Industry Trends Table 2. Targeted Drugs for Neurodegenerative Diseases Industry Drivers Table 3. Targeted Drugs for Neurodegenerative Diseases Industry Opportunities and Challenges Table 4. Targeted Drugs for Neurodegenerative Diseases Industry Restraints Table 5. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Targeted Drugs for Neurodegenerative Diseases Revenue Share by Company (2021-2026) Table 7. Global Targeted Drugs for Neurodegenerative Diseases Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Targeted Drugs for Neurodegenerative Diseases Key Company Manufacturing Base & Headquarters Table 9. Global Targeted Drugs for Neurodegenerative Diseases Company, Product Type & Application Table 10. Global Targeted Drugs for Neurodegenerative Diseases Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Targeted Drugs for Neurodegenerative Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Injection Table 16. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type (2021-2026) Table 20. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Parkinson's Disease (PD) Table 22. Significant Companies of Huntington's Disease (HD) Table 23. Significant Companies of Multiple Sclerosis (MS) Table 24. Significant Companies of Tardive Dyskinesia (TD) Table 25. Significant Companies of Alzheimer's Disease (AD) Table 26. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application (2021-2026) Table 30. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application (2027-2032) Table 31. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Region (2021-2026) Table 34. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Region (2027-2032) Table 36. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Market Share by Country (2021-2026) Table 39. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Market Share by Country (2027-2032) Table 41. Eisai Inc. Company Information Table 42. Eisai Inc. Business Overview Table 43. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 45. Eisai Inc. Recent Development Table 46. Teva Company Information Table 47. Teva Business Overview Table 48. Teva Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Teva Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 50. Teva Recent Development Table 51. NOVARTIS Company Information Table 52. NOVARTIS Business Overview Table 53. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 55. NOVARTIS Recent Development Table 56. Green Valley Company Information Table 57. Green Valley Business Overview Table 58. Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Green Valley Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 60. Green Valley Recent Development Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Roche Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 65. Roche Recent Development Table 66. Lundbeck Company Information Table 67. Lundbeck Business Overview Table 68. Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 70. Lundbeck Recent Development Table 71. Eli Lilly Company Information Table 72. Eli Lilly Business Overview Table 73. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 75. Eli Lilly Recent Development Table 76. Biogen Company Information Table 77. Biogen Business Overview Table 78. Biogen Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Biogen Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 80. Biogen Recent Development Table 81. UCB Company Information Table 82. UCB Business Overview Table 83. UCB Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. UCB Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 85. UCB Recent Development Table 86. Supernus Pharmaceuticals Company Information Table 87. Supernus Pharmaceuticals Business Overview Table 88. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 90. Supernus Pharmaceuticals Recent Development Table 91. Sumitomo Pharma Company Information Table 92. Sumitomo Pharma Business Overview Table 93. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 95. Sumitomo Pharma Recent Development Table 96. Sanofi Company Information Table 97. Sanofi Business Overview Table 98. Sanofi Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Sanofi Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 100. Sanofi Recent Development Table 101. Neurocrine Company Information Table 102. Neurocrine Business Overview Table 103. Neurocrine Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 105. Neurocrine Recent Development Table 106. Kyowa Kirin Company Information Table 107. Kyowa Kirin Business Overview Table 108. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 110. Kyowa Kirin Recent Development Table 111. Janssen Company Information Table 112. Janssen Business Overview Table 113. Janssen Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Janssen Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 115. Janssen Recent Development Table 116. Bristol-Myers Squibb Company Information Table 117. Bristol-Myers Squibb Business Overview Table 118. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 120. Bristol-Myers Squibb Recent Development Table 121. Acadia Pharmaceuticals Inc. Company Information Table 122. Acadia Pharmaceuticals Inc. Business Overview Table 123. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 125. Acadia Pharmaceuticals Inc. Recent Development Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Targeted Drugs for Neurodegenerative Diseases Product Image Figure 2. Global Targeted Drugs for Neurodegenerative Diseases Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032) & (US$ Million) Figure 4. Global Targeted Drugs for Neurodegenerative Diseases Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Injection Image Figure 9. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type (2021-2032) Figure 12. Parkinson's Disease (PD) Image Figure 13. Huntington's Disease (HD) Image Figure 14. Multiple Sclerosis (MS) Image Figure 15. Tardive Dyskinesia (TD) Image Figure 16. Alzheimer's Disease (AD) Image Figure 17. Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application (2021-2032) Figure 20. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032) & (US$ Million) Figure 23. North America Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032) & (US$ Million) Figure 29. South America Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Parkinson's Disease (PD)
  • Huntington's Disease (HD)
  • Multiple Sclerosis (MS)
  • Tardive Dyskinesia (TD)
  • Alzheimer's Disease (AD)
Companies covered
  • Eisai Inc.
  • Teva
  • NOVARTIS
  • Green Valley
  • Roche
  • Lundbeck
  • Eli Lilly
  • Biogen
  • UCB
  • Supernus Pharmaceuticals
  • Sumitomo Pharma
  • Sanofi
  • Neurocrine
  • Kyowa Kirin
  • Janssen
  • Bristol-Myers Squibb
  • Acadia Pharmaceuticals Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Targeted Drugs for Neurodegenerative Diseases Market Dynamics
  1. 2.1 Targeted Drugs for Neurodegenerative Diseases Industry Trends
  2. 2.2 Targeted Drugs for Neurodegenerative Diseases Industry Drivers
  3. 2.3 Targeted Drugs for Neurodegenerative Diseases Industry Opportunities and Challenges
  4. 2.4 Targeted Drugs for Neurodegenerative Diseases Industry Restraints
3 Targeted Drugs for Neurodegenerative Diseases Market by Company
  1. 3.1 Global Targeted Drugs for Neurodegenerative Diseases Company Revenue Ranking in 2025
  2. 3.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Company (2021-2026)
  3. 3.3 Global Targeted Drugs for Neurodegenerative Diseases Company Ranking (2024-2026)
  4. 3.4 Global Targeted Drugs for Neurodegenerative Diseases Company Manufacturing Base and Headquarters
  5. 3.5 Global Targeted Drugs for Neurodegenerative Diseases Company Product Type and Application
  6. 3.6 Global Targeted Drugs for Neurodegenerative Diseases Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Targeted Drugs for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Targeted Drugs for Neurodegenerative Diseases Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Targeted Drugs for Neurodegenerative Diseases Market by Type
  1. 4.1 Targeted Drugs for Neurodegenerative Diseases Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Type
  5. 4.2.1 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Type (2021-2032)
  7. 4.2.3 Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type (2021-2032)
5 Targeted Drugs for Neurodegenerative Diseases Market by Application
  1. 5.1 Targeted Drugs for Neurodegenerative Diseases Application Introduction
  2. 5.1.1 Parkinson's Disease (PD)
  3. 5.1.2 Huntington's Disease (HD)
  4. 5.1.3 Multiple Sclerosis (MS)
  5. 5.1.4 Tardive Dyskinesia (TD)
  6. 5.1.5 Alzheimer's Disease (AD)
  7. 5.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Application
  8. 5.2.1 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Application (2021-2032)
  10. 5.2.3 Global Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application (2021-2032)
6 Targeted Drugs for Neurodegenerative Diseases Regional Value Analysis
  1. 6.1 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Region (2021-2032)
  3. 6.2.1 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Region: 2021-2026
  4. 6.2.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032)
  7. 6.3.2 North America Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032)
  10. 6.4.2 Europe Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032)
  16. 6.6.2 South America Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Country, 2025 VS 2032
7 Targeted Drugs for Neurodegenerative Diseases Country-level Value Analysis
  1. 7.1 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Country (2021-2032)
  3. 7.2.1 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Country (2021-2026)
  4. 7.2.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Targeted Drugs for Neurodegenerative Diseases Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Targeted Drugs for Neurodegenerative Diseases Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai Inc.
  2. 8.1.1 Eisai Inc. Company Information
  3. 8.1.2 Eisai Inc. Business Overview
  4. 8.1.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  6. 8.1.5 Eisai Inc. Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 NOVARTIS
  14. 8.3.1 NOVARTIS Company Information
  15. 8.3.2 NOVARTIS Business Overview
  16. 8.3.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  17. 8.3.4 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  18. 8.3.5 NOVARTIS Recent Developments
  19. 8.4 Green Valley
  20. 8.4.1 Green Valley Company Information
  21. 8.4.2 Green Valley Business Overview
  22. 8.4.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  24. 8.4.5 Green Valley Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Lundbeck
  32. 8.6.1 Lundbeck Company Information
  33. 8.6.2 Lundbeck Business Overview
  34. 8.6.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  36. 8.6.5 Lundbeck Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Biogen
  44. 8.8.1 Biogen Company Information
  45. 8.8.2 Biogen Business Overview
  46. 8.8.3 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biogen Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  48. 8.8.5 Biogen Recent Developments
  49. 8.9 UCB
  50. 8.9.1 UCB Company Information
  51. 8.9.2 UCB Business Overview
  52. 8.9.3 UCB Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  53. 8.9.4 UCB Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  54. 8.9.5 UCB Recent Developments
  55. 8.10 Supernus Pharmaceuticals
  56. 8.10.1 Supernus Pharmaceuticals Company Information
  57. 8.10.2 Supernus Pharmaceuticals Business Overview
  58. 8.10.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  60. 8.10.5 Supernus Pharmaceuticals Recent Developments
  61. 8.11 Sumitomo Pharma
  62. 8.11.1 Sumitomo Pharma Company Information
  63. 8.11.2 Sumitomo Pharma Business Overview
  64. 8.11.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  66. 8.11.5 Sumitomo Pharma Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Neurocrine
  74. 8.13.1 Neurocrine Company Information
  75. 8.13.2 Neurocrine Business Overview
  76. 8.13.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  78. 8.13.5 Neurocrine Recent Developments
  79. 8.14 Kyowa Kirin
  80. 8.14.1 Kyowa Kirin Company Information
  81. 8.14.2 Kyowa Kirin Business Overview
  82. 8.14.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  84. 8.14.5 Kyowa Kirin Recent Developments
  85. 8.15 Janssen
  86. 8.15.1 Janssen Company Information
  87. 8.15.2 Janssen Business Overview
  88. 8.15.3 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Janssen Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  90. 8.15.5 Janssen Recent Developments
  91. 8.16 Bristol-Myers Squibb
  92. 8.16.1 Bristol-Myers Squibb Company Information
  93. 8.16.2 Bristol-Myers Squibb Business Overview
  94. 8.16.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  96. 8.16.5 Bristol-Myers Squibb Recent Developments
  97. 8.17 Acadia Pharmaceuticals Inc.
  98. 8.17.1 Acadia Pharmaceuticals Inc. Company Information
  99. 8.17.2 Acadia Pharmaceuticals Inc. Business Overview
  100. 8.17.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  102. 8.17.5 Acadia Pharmaceuticals Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst